

# Ian C Lawrance

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1815881/ian-c-lawrance-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30  
papers

6,105  
citations

17  
h-index

31  
g-index

31  
ext. papers

7,057  
ext. citations

9.7  
avg, IF

4.02  
L-index

#	Paper	IF	Citations
30	Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumors in a Mouse Model of Colitis-Associated Colorectal Cancer. <i>Nutrition and Cancer</i> , <b>2021</b> , 1-10	2.8	1
29	The role of a plant-based diet in the pathogenesis, etiology and management of the inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 137-145	4.2	9
28	Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis. <i>Experimental Biology and Medicine</i> , <b>2020</b> , 245, 1697-1707	3.7	2
27	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 93-102	4.5	10
26	Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 273-280	2.4	7
25	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 653-661	1.5	18
24	Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 135-145	4	15
23	High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis. <i>Scientific Reports</i> , <b>2018</b> , 8, 11511	4.9	28
22	Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1248-1255	6.9	31
21	Serologic antibodies in relation to outcome in postoperative Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1195-1203	4	15
20	Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. <i>BMC Medical Genetics</i> , <b>2017</b> , 18, 94	2.1	20
19	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet, The</i> , <b>2016</b> , 387, 156-67	40	449
18	Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 9104-9116	5.6	16
17	Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. <i>Gastroenterology</i> , <b>2016</b> , 151, 110-9	13.3	183
16	Acute severe ulcerative colitis: Changing treatment paradigms. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31 Suppl 1, 16	4	
15	The multidisciplinary team. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31 Suppl 1, 17	4	2
14	Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 761-8	5.9	5

13	Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. <i>Gastroenterology</i> , <b>2015</b> , 148, 938-947.e1	13.3	197
12	Animal Models of IBD-Associated CRC and Colorectal Cancer Tumorigenesis. <i>Clinical Medicine Insights Therapeutics</i> , <b>2015</b> , 7, CMT.S18489	0	3
11	Effect of intestinal resection on quality of life in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 452-62	1.5	20
10	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet, The</i> , <b>2015</b> , 385, 1406-17	17	355
9	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , <b>2014</b> , 46, 1131-4	36.3	130
8	Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1147-65	1.5	109
7	Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 598-606	1.5	74
6	Crohn's disease and smoking: is it ever too late to quit?. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e665-71	1.5	33
5	Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1490-8	4.5	27
4	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , <b>2012</b> , 491, 119-24	50.4	3239
3	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , <b>2011</b> , 43, 246-52	36.3	1028
2	Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1732-8	4	63
1	Small bowel MRI enteroclysis or follow through: which is optimal?. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 5300-6	5.6	16